Last update: Aug. 22, 2019
Not risky for breastfeeding or infant.
Selective agonist for the vascular receptor of 5-hydroxytryptamine-1 (5-HT1, serotonin) with vasoconstrictor action at the intracranial level.
Indicated in acute migraine attack.
Oral administration in a daily dose.
It is excreted in breastmilk in clinically insignificant amounts: 0.02% of the maternal dose (AEMPS-Pfizer 2013).
Its low oral bioavailability impedes its transfer from breastmilk into infant plasma, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.
Several expert authors consider its use to be safe or probably safe during breastfeeding (Hale 2019, Briggs 2017, Amundsen 2015, Davanzo 2014, Hutchinson 2013, Duong 2010).
Its use, usually in isolated doses, makes the occurrence of adverse effects in infants unlikely (Jürgens 2009).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM